Obesity Overweight
Conditions
Interventions
This research will have 2 stages: I) Development of a practical and low-cost genetic kit for use in the Unified Health System. The kit will determine the presence of single nucleotide polymorphisms of
40–55 years) and BMI range (27.0–29.9 kg/m²
30.0–34.9 kg/m²
35.0–40.0 kg/m²). As for masking, it will be open (not blinded). Study participants will be recruited from Basic Health Units and the university community in the city of Viçosa/Minas Gerais, Brazil, a
Sponsors
Departamento de Nutrição e Saúde da Universidade Federal de Viçosa
Universidade Federal de Viçosa
Eligibility
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: Men and women will be included; between 20 and 55 years old; overweight; high waist circumference; excess body fat associated with at least one of the other components of Metabolic Syndrome; obesity and excess body fat independent of the presence of the other components of Metabolic Syndrome
Exclusion criteria
Exclusion criteria: Pregnant women; lactating women; women in menopause; athletes; shift workers; people with physical and/or intellectual disabilities; intolerance or food allergies to the test foods; type 1 diabetes mellitus; autoimmune diseases or use of immunosuppressants; hormonal disease; digestive disease or alterations; carriers of inflammatory bowel or liver diseases; chronic kidney disease; pancreatitis; cardiovascular diseases; eating disorders; cancer; infectious episode in the last month; history of illicit drug use and/or alcohol consumption greater than 21 and greater than 14 units/week for men and women, respectively; having undergone bariatric surgery; indicating weight instability (5% of usual weight) in the last three months; habitual consumption of granola, nuts, whole grains or seeds (sesame, pumpkin and sunflowerseeds, flaxseed) >30 g/day; following a vegan, vegetarian or dietary restriction diet (gluten, lactose); use of anti-inflammatory drugs, corticosteroids, antipsychotics, antidepressants that may affect appetite and energy metabolism; use of vitamin, mineral and omega-3 supplements; use of fiber supplements (psyllium, inulin); not having participated in nutritional interventions in the last three months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find an estimated weight loss of 5 to 10% of the initial weight, determined through anthropometric and body composition measurements at the initial moments, at 12 weeks and at the end of 5 months (20 weeks) of intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Attenuation of the effects of single nucleotide polymorphisms of risk on (epi)genetic and metagenomic markers, as well as serum cardiometabolic markers, satiety markers and intestinal permeability markers with personalized nutritional intervention (with genetic score). Verified by the collection and separation of biological samples for the evaluation of biochemical markers, interleukins and plasma markers of neuroendocrine control of satiety. Genomic DNA from peripheral blood cells will be extracted with the help of the Blood-Animal-Plant DNA Preparation Kit and the analysis of gene expression with deoxyribonucleic acid methylation will be performed using the EpiTect II DNA Methylation Enzyme® kit. The Polymerase Chain Reaction technique will be used to evaluate the expression of genes and miRNA involved in satiety and cardiometabolic risk;Improvement of indicators of quality of life, self-esteem and quality of food intake in individuals with obesity undergoing nutritional intervention aimed at the genetic score. Verified by assessing food consumption, through three 24-hour food recalls, referring to two weekdays and one weekend day; questionnaires will be applied to understand aspects related to the practice of habitual physical activity, chronotype, self-esteem and quality of life | — |
Countries
BR
Contacts
Public ContactHelen;Karla Hermsdorff;Balbino
Universidade Federal de Viçosa;Universidade Federal de Viçosa
Outcome results
None listed